SGS M-Scan News

News Archive Show only
06
2012

SGS M-Scan Open Day 2012

19. Jun 2012

Join SGS M-Scan for a one-day seminar to stay abreast of the current regulatory environment and learn about optimizing your Biopharmaceutical development. The day will include a selection of scientific talks, case studies and face-to-face meetings with some of our experts and key industry players who will discuss the latest updates on:

  • The biologics R&D market and trends; a presentation by Frost & Sullivan
  • Biophysical analysis
  • Extractable & Leachables
  • Antibody characterization
  • Methods for characterization of protein glycosylation
  • Regulatory/technical issues for biopharma & biosimilar products

We look forward to seeing you at this event in the DeVere Wokefield Park Hotel, Reading, UK, June 19 from 10:00am to 4:40pm for this complementary scientific seminar. View the complete program and venue details.

 

REGISTER NOW

 

05
2012

SGS Announces investment in new Life Sciences Services Facility in Mumbai, India

30. May 2012

SGS will open a second Indian analytical laboratory in Mumbai, fully operated by mid- 2012, to meet the booming local demand from large generic and multinational pharmaceutical companies.

 

FOR MORE INFORMATION, PLEASE CONTACT:

Ferdinand Dabu

Global Marketing Director, Life Science Services

SGS, 75 Passaic Avenue, Fairfield, NJ 07004, USA

Email: ferdinand.dabu@sgs.com

Website: www.sgs.com/lifescience

05
2012

SGS Acquires Vitrology Limited, Glasgow, UK and enhances offering for Biologic Therapeutics Testing

21. May 2012

SGS announced on May 18th the acquisition of Vitrology Limited based in Glasgow, UK. Vitrology is a biopharmaceutical Contract Testing Organization and a dynamic force in the biosafety testing sector of the pharmaceutical industry. Founded in 2007 and privately owned, Vitrology has 38 employees with sales agents in North America and Asia. In 2011, it generated revenue in excess of £3 million.

Vitrology offers a range of validated assays and develops new services in the following areas:

- Cell Bank and Virus Seeds characterization per major compendia, regulatory and ICH guidelines

- Raw material and bulk harvest testing (sterility, mycoplasma, viruses, ...)

- Final product testing for Residual DNA

- Regulatory and safety consultancy services

- Custom development assays

 

FOR MORE INFORMATION, PLEASE CONTACT:

Florent Hédiard

Global Marketing Director, Life Science Services

SGS, 173 rue de la Croix Nivert, 75015 Paris, France

Email: florent.hediard@sgs.com

Websites: www.sgs.com/lifescience - www.vitrologybiotech.com

05
2012

SGS Life Science Services adds Formulation Development in Lincolnshire, IL laboratory

01. May 2012

SGS Life Science Services adds Formulation Development in Lincolnshire, IL laboratory. This service portfolio expansion encompasses liquid and lyophilized development services, as well as technology transfer to cGMP manufacturing. Some of the pre-formulation and formulation capabilities include: characterizing physico-chemical properties; improving solubility; developing stability assays; target product profiling; screening buffers, pH, surfactants and stabilizers; container-closure and pre-filled syringe compatibility and selection, and ANDA product development.

 

FOR MORE INFORMATION, PLEASE CONTACT:

Ferdinand Dabu

Global Marketing Director, Life Science Services

SGS, 75 Passaic Avenue, Fairfield, NJ 07004, USA

Email: ferdinand.dabu@sgs.com

Website: www.sgs.com/lifescience

06
2011

Newsletters - June 2011

01. Jun 2011

Glycosylation is one of the mostly widely observed and structurally diverse forms of Post Translational Modifications of proteins. The diversity of structure and the significance of the glycosylation means that close attention must be paid to the nature of glycans on any glycoprotein biopharmaceutical and is an important issue for regulatory agencies.

 

The featured article this quarter focuses on: “ How do you perform glycoprotein characterization to comply with the ICH Q6B guidelines”? You can read the article at http://www.sgs.com/lsnewsqc/lsnewsqc-june-2011-issue/glycosylation-of-proteins-structure-function-and-analysis.htm

 

For more information about SGS M-Scan services on “Glycoprotein Analysis” contact us by email or visit our webpage.

03
2011

Newsletters - March 2011

01. Mar 2011

The first newsletter in 2011 opens with a review article on the application of mass spectrometry for protein analysis by Dr. Howard Morris, Emeritus Professor Imperial College London and M-Scan Founder.

 

This short paper gives the essential background to an understanding of biopharmaceutical characterization by mass spectrometry and its importance in accelerating the processes leading to the approval by the regulator of well- characterized new drugs. Products involved include monoclonal antibodies, hormones and cytokines, and the new generation of Biosimilars and Biobetters resulting from patent expiration of the originator products. Subsequent newsletters from SGS M-Scan experts will provide more detail of the glycosylation, disulfide bridge assignment and monoclonal antibody specifics of the MS characterization protocols offered by SGS M-SCAN to serve its clients’ needs.

 

You can read the article at http://www.sgs.com/lsnewsqc/lsnewsqc-march-2011-issue/protein-and-glycoprotein-characterisation-by-mass-spectrometry.htm

 

For more information about SGS M-Scan services on “Protein Analysis” contact us by email or visit our webpage.

01
2011

Name Change

31. Jan 2011

We are proud to announce that we are changing company name from M-Scan to SGS M-Scan.

 

The name change is due to the recent acquisition by SGS, the World’s leading inspection, verification, testing and certification company.  Together, we will continue to provide our clients with the same high quality services, without interruption, on which we have built our reputation within the industry.

 

Are there any other changes?


The only change will be an increased battery of services.

 

Management will remain the same and all contact details (phone numbers and emails) will remain the same, but you may notice responses are sent from our new email domains firstname.lastname@sgs.com. Please continue to liaise with your SGS M-Scan representative.

11
2010

SGS Group acquires M-Scan Group

01. Nov 2010

 

The M-Scan Group is pleased to announce its acquisition by SGS, the World’s leading inspection, verification, testing and certification company. Our founder, Professor Howard Morris, comments “We see compelling synergies between the respective current testing activities of M-Scan and SGS. This is an exciting opportunity to provide our customers with an enhanced range of services — complementing our core strengths in advanced mass spectrometric and chromatographic analysis in the fields of biopharmaceutical characterisation, oil/petroleum analysis and environmental monitoring. I look forward with enthusiasm to continuing my consultancy / advisory role within the new framework.”

 

SGS is recognised as the global benchmark for quality and integrity, employing 59,000 people and operating a network of more than 1,000 offices and laboratories around the World. The four laboratories of the M-Scan Group will join SGS’ existing global Life Science Services network of 14 laboratories in the USA, Belgium, Canada, China, France, Germany, India, Singapore, Taiwan and Thailand.

 

Dr Andrew Reason remains as Managing Director of M-Scan Ltd and GmbH, Dr. Mark Rogers remains Director of M-Scan INC, Dr. Luc-Alain Savoy remains Director of M-Scan SA and Dr Fiona Greer continues as Global Director of QA/QC and Marketing. We will continue to provide the same high quality services to our valued customers without interruption, and the only expected change will be an enhancement of the range of services we can provide. All CDAs / Contracts with M-Scan remain valid. Our contact details remain exactly the same.

 

Together M-Scan and SGS will continue to provide you with World-leading bespoke chemical testing as well as high-end GLP/GMP contract analytical services, consultancy and training based on Mass Spectrometry and Chromatography.

 

Please do not hesitate to contact us if you would like any further information regarding this exciting development.

10
2010

FDA Audit at M-Scan Ltd

05. Oct 2010

M-Scan Ltd (Wokingham, UK) was successfully audited by the FDA in connection with a client submission. No written objections were received.

08
2010

GMP re-inspection at M-Scan SA

26. Aug 2010

M-Scan SA (Geneva) successfully completed a routine inspection for GMP compliance. Swissmedic will shortly issue an updated GMP certificate.